BCAL Diagnostics Develops Blood Test for Breast Cancer Recurrence Monitoring

Why It Matters

Early, non‑invasive detection of recurrence could improve cure rates and lower surveillance costs, addressing a major unmet need in breast‑cancer survivorship care.

Key Takeaways

• BREASTEST Monitor shows 91% sensitivity in early recurrence detection
• Test achieved 95% negative predictive value in women 50+
• Targets over 4 million US breast cancer survivors for surveillance
• Aims to complement imaging, potentially reducing costly mammography reliance
• BCAL holds exclusive ClearNote Health licence for multi‑cancer blood tests

Pulse Analysis

Recurrence monitoring remains a blind spot in breast‑cancer care, with up to 15% of survivors experiencing a local return of disease years after initial therapy. Conventional imaging—mammography, ultrasound, MRI—carries high costs, limited accessibility, and can miss up to one‑third of recurrences, especially in dense‑breasted or scarred tissue. A blood‑based assay like BREASTEST Monitor offers a scalable, patient‑friendly alternative that can be administered more frequently, potentially catching tumors earlier when they are most treatable.

BCAL's development process leveraged over 450 reference samples to train a proprietary algorithm, then validated it on a held‑out cohort of 100 specimens, including 23 confirmed recurrences. The resulting 91% sensitivity and 95% negative predictive value exceed many imaging benchmarks, suggesting the test could reliably rule out disease and spare patients unnecessary scans. By serving as an adjunct, the assay may triage patients who truly need imaging, thereby reducing overall diagnostic expenditures and accelerating clinical decision‑making.

The market opportunity is sizable: more than 4 million breast‑cancer survivors in the United States alone require ongoing surveillance, and the global monitoring market is projected to reach $4.5 billion by 2030. Beyond cost savings, a non‑invasive test could alleviate the psychological burden of recurrence anxiety, offering reassurance through regular, simple blood draws. As BCAL pursues broader validation—including younger cohorts—the test could evolve into a standalone surveillance tool, reinforcing the broader shift toward liquid biopsies across oncology and cementing BCAL's role in the next generation of cancer diagnostics.